Sourav Bandyopadhyay, PhD

What I do

I seek to understand, at the systems level, how biological networks within cancer cells are fundamentally different from those in normal cells. Using a variety of experimental techniques, I design new platforms for the rational application of personalized medicine and the design of combination cancer therapies.

Professional background


Sourav Bandyopadhyay obtained his PhD in Bioinformatics and Systems Biology with Trey Ideker (UC San Diego) where he made seminal contributions to our understanding of the organization and plasticity of physical and genetic interaction networks, (Bandyopadhyay et al. Science 2010, Nature Methods 2010, PLoS Computational Biology 2008). In 2010 he began an independent research career through the prestigious UCSF faculty fellowship designed to provide early independence to the world’s best scientists.

The Bandyopadhyay lab employs new cellular and molecular technologies to tackle the most urgent and clinically important problems in cancer therapy, including functional genomics, drug screens, proteomics and single cell approaches. Critically, these technologies often generate the scale and complexity of data that necessitate the development of new computational algorithms to maximize their impact and fully understand their relevance in the clinic. The lab is focused on identifying mechanisms of drug resistance and targetable synthetic lethal interactions in breast and lung cancers since these diseases are deadly in the metastatic setting and demonstrate suboptimal tumor responses even with out best, most targeted therapies. We are committed to the identification, mechanistic dissection and clinical translation of new targets and target combinations through broad collaborations with biotechnologists, chemists, clinicians and pharma.

Research keywords

  • networks
  • Cancer Biology
  • precision medicine
  • pathways
  • bioinformatics
  • pharmacogenomics
  • systems biology
  • pharmacogenetics
  • Protein Interaction Mapping
  • Protein Kinase Inhibitors
  • Gene Regulatory Networks
  • Aurora Kinase A
  • Drug Resistance, Neoplasm
  • Breast Neoplasms
  • Cell Line, Tumor
  • Azepines
  • Plant Proteins
  • Antineoplastic Agents
  • Epistasis, Genetic
  • Synthetic Lethal Mutations
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Triple Negative Breast Neoplasms